Steris plc stock (IE00BFY8C754): Q4 earnings due today with consensus EPS 2.89

Steris plc (NYSE:STE) releases Q4 fiscal 2026 earnings after market close today, May 11, with analysts forecasting revenue of $1.60B and EPS of $2.89. Director changes include Pierre Boulud joining the board.

Steris plc is scheduled to report its fiscal fourth quarter 2026 earnings on May 11, 2026, after the market close, according to MarketBeat as of 05/11/2026. Consensus estimates call for revenue of $1.60 billion and earnings per share of $2.89, reflecting expectations of steady growth in infection prevention and healthcare products. The earnings call is set for 16:30 ET, highlighting the company's performance in a key sector for US healthcare investors.

Separately, Steris announced board changes with Pierre Boulud, former CEO of bioMérieux and BCG partner, joining the board, while Richard Breeden plans to step down, as reported by DirectorMoves as of recent update. These developments come amid anticipation for the earnings, which are critical for the NYSE-listed firm traded under ticker STE.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Healthcare equipment & infection prevention
• Headquarters/country: Ireland (operations in US)
• Core markets: US, Europe, global healthcare
• Key revenue drivers: Sterilization services, consumables, equipment
• Home exchange/listing venue: NYSE (STE)
• Trading currency: USD

Steris plc: core business model

Steris plc provides infection prevention and other procedural products and services worldwide, focusing on healthcare, pharmaceutical, and medical device industries. The company offers sterilization technologies, outsourced reprocessing, and capital equipment through segments including Healthcare, Applied Sterilization Technologies, and Life Sciences. With a strong US presence via NYSE listing, Steris supports hospitals and labs in maintaining sterile environments, a vital need amplified post-pandemic for American investors tracking healthcare resilience.

STERIS generates recurring revenue from consumables and services, which account for a significant portion of sales, alongside equipment sales. Fiscal 2026 results, due today, will provide updated insights into this model, as per consensus from Intellectia AI as of 05/11/2026.

Main revenue and product drivers for Steris plc

Key drivers include the Healthcare segment's consumables like sterilization wraps and indicators, alongside service contracts for outsourced instrument reprocessing. Revenue growth is supported by demand in US hospitals, where infection control remains a priority. Consensus for Q4 2026 projects $1.60B total revenue, building on prior periods' expansion in life sciences tools for pharma manufacturing.

Applied Sterilization Technologies provides contract sterilization for medical devices, serving US medtech firms. Recent board addition of Pierre Boulud may bolster strategic focus on these areas, given his bioMérieux background in diagnostics and infection control.

Industry trends and competitive position

The infection prevention market grows with rising hospital-acquired infection concerns in the US, where Steris competes with firms like Boston Scientific and Becton Dickinson, per MarketBeat competitor data. Steris differentiates via integrated service offerings, appealing to US healthcare providers seeking efficiency.

Why Steris plc matters for US investors

Listed on NYSE, Steris derives substantial revenue from the US market, making it relevant for investors exposed to American healthcare spending. Earnings today could signal trends in hospital budgets and medtech demand, key for portfolios focused on defensive healthcare plays.

Conclusion

Steris plc approaches its Q4 2026 earnings release with solid consensus expectations and recent board refresh. Investors will watch for confirmation of revenue growth and guidance amid competitive pressures. The company's role in US infection control underscores its strategic position, though outcomes depend on execution and market dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.